

## Oncology Today with Dr Neil Love: Recent Updates in the Management of HER2-Low Breast Cancer

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. In the Phase III DESTINY-Breast04 trial evaluating trastuzumab deruxtecan (T-DXd) versus treatment of physician's choice for patients with HER2-low metastatic breast cancer, which of the following treatment-emergent adverse events of any grade was NOT more common with T-DXd than with treatment of physician's choice?

  - a. Nausea
  - b. Fatigue
  - c. Neutropenia**
  - d. Alopecia
2. Which of the following results was reported with T-DXd for patients with hormone receptor (HR)-positive breast cancer in the DESTINY-Breast04 trial?

  - a. Significantly improved progression-free and overall survival**
  - b. Significantly improved progression-free but not overall survival
  - c. No significant improvement in progression-free or overall survival
3. Approximately what proportion of breast cancer cases are HER2 low?

  - a. 5%
  - b. 20%
  - c. 35%
  - d. 50%**
4. Which of the following ongoing or planned trials will evaluate T-DXd versus physician's choice of chemotherapy for patients with chemotherapy-naïve, HR-positive HER2-low or HER2-ultralow metastatic breast cancer?

  - a. DESTINY-Breast06**
  - b. DESTINY-Breast08
  - c. BEGONIA
  - d. TRIO-US B-12 TALENT
5. Which of the following adverse events of special interest was most common with T-DXd in the DESTINY-Breast04 trial?

  - a. Left ventricular ejection fraction decrease
  - b. Interstitial lung disease/pneumonitis**
  - c. Cardiac failure